Beckman Coulter (BEC) Misses Q3 EPS by 4c
More News related to BEC
- Beckman Coulter to Present at the 27th Annual J.P. Morgan Healthcare Conference
- Beckman Coulter (BEC) Receives FDA Approval for its UniCel(R) DxH 800
- Beckman Coulter Announces FDA Clearance of UniCel(R) DxH 800
- Beckman Coulter Announces Release of Three New Work Cells
- Beckman Coulter (BEC) Affirms FY08 Guidance; Issues FY09 Preliminary Outlook
More News related to Earnings
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Beckman Coulter (NYSE: BEC) reports Q3 EPS of $0.78, 4 cents worse than the analyst estimate of $0.82. Revenue for the quarter was $758.8 million, versus the consensus of $739.50 million.
"Based on current exchange rates, full year revenue growth should be in the range of 12% to 13%. We expect 2008 adjusted operating margin to be on par with prior year. The outlook for adjusted non-operating expense is about $45 million. Adjusted pretax profit growth should be around 10%, with an adjusted tax rate of 26% to 27%. Consequently, our adjusted EPS outlook remains at $3.55 to $3.65 based on a share count of about 64.5 million. Adjusted EBITDA should be about $625 million. Capital expenditures are expected to be approximately $300 million, and depreciation and amortization should be around $260 million." (FY EPS consensus is $3.62)
Related Categories
EarningsGuidance
Stocks Mentioned
-0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
